2-Fluorodeschloroketamine

The live row is materially correct that unauthorized possession, production and sale of 2-FDCK are prohibited, but it names the wrong governing regime and overstates the rule without lawful-purpose and personal-use qualifications. BGBl. II Nr. 394/2024 expressly added 2-Fluorodeschloroketamin, 2-FDCK to SV Anhang IV.1 effective at the end of 19 December 2024. The current consolidated SV treats Anhang IV.1 substances as Suchtgifte under SMG § 2(2). Current SMG § 5(1) limits Suchtmittel dealings to medical, dental, veterinary or scientific purposes under the statute, while § 27(1) criminalizes unauthorized acquisition, possession, production, transport, import, export, offering, transfer and supply and § 27(2) provides a lower maximum penalty for conduct exclusively for personal use. NPSG § 2(2) excludes SMG-subject substances, so the corrected entry should cite SV/SMG rather than NPSG.

Corrected the legacy conditional wording to the definitive compound-specific Canadian classification. Health Canada's official NPS table expressly identifies fluorodeschloroketamine (including 2-FDCK) as controlled under CDSA Schedule I, item 14, line 1; the current CDSA supplies the operative item 14 heading and analogue definition. The 2026 Health Canada classification page independently places 2-Fluorodeschloroketamine in ‘Ketamine and analogues.’ The exact material should still be understood as the named 2-FDCK substance rather than an unspecified fluorodeschloroketamine isomer; the 2022 table lists multiple fluorodeschloroketamine isomers. This dossier addresses federal Canadian law and does not assess provincial rules or any specific authorization/exemption.

The live row is substantively correct that 2-fluorodeschloroketamine is the Italian Tabella I substance Fluoroketamina, but the canonical status and possession wording require correction. The 2020 Ministry decree expressly lists Fluoroketamina, its chemical name, 2-fluorodescloroketamina and 2-FDCK in Tabella I. Current D.P.R. 309/1990 art. 73 criminalizes unauthorized production, sale, supply, distribution, trade and related non-personal-use import/export/acquisition/receipt/possession. Current art. 75 separately treats illicit personal-use import/export/acquisition/receipt/possession of Tabella I substances as an administrative offense, so the old statement that all possession is prohibited without qualification is overstated. The canonical prohibited status reflects the ordinary unlicensed prohibition on trafficking and other non-personal-use conduct, while preserving this personal-use qualification.

The legacy row's plain Illegal label is corrected to the canonical prohibited status and a current legal instrument. Latvia does not need an exact-name listing for this compound: Annex 2 List I section 11(9) is a description-defined psychotropic category whose structural elements match the verified 2-fluorodeschloroketamine identity. The conclusion concerns ordinary unlicensed handling; the Latvian statute preserves a narrow permit route for specified scientific and training uses. The former Cabinet Regulation No. 847 is not relied on because it is repealed; the current source is Annex 2 to the Criminal Law application statute as cross-referenced by section 3 of the legal-trade law.

The legacy entry is supported and can be normalized to canonical prohibited. The exact compound is expressly listed by Läkemedelsverket as 2-fluorodeskloroketamin, 2-(2-fluorofenyl)-2-(metylamino)cyklohexan-1-on, Swedish narcotics list I and international list P II. Under the current Swedish narcotics-control statutes, unauthorized possession, use, import/export, manufacture and trade are prohibited; narrow authorized medical, scientific, societal-benefit and industrial purposes remain possible under the cited permission rules. This dossier does not assert that every possible salt, formulation or future amendment has identical treatment beyond the schedule's own applicable salts/isomers language.

The legacy Turkey entry is supported and normalized to canonicalStatus prohibited. Decision No. 1335 is a direct named listing of 2-FDCK under Law No. 2313 Article 19, so the result does not depend on a generic or analogue theory. The legal consequence should be stated as unauthorized handling being prohibited: Article 188(1) covers unlicensed manufacture/import/export, Article 188(3) covers unlicensed domestic supply and possession-type conduct, and Article 191 supplies a separate personal-use route with its own deferred-prosecution and supervised-release framework. This dossier does not assert that every conceivable official scientific or other narrowly authorized handling is impossible, nor does it decide a fact-specific charge, quantity or permit question. The current consolidated Law No. 2313 record and the 2026 Decision No. 10851 currentness check did not identify repeal or displacement of the 2019 named inclusion.

The live legacy entry is materially imprecise. Current Belgian primary law expressly names 2-FDCK in Annex IIB, inserted by the 19 December 2025 Royal Decree effective 26 January 2026, so the entry should be corrected from the noncanonical blanket-ban wording to a named scheduled psychotropic substance. The canonical prohibited status reflects the Royal Decree's prior-authorization requirement for ordinary possession and other handling plus its penalty provision; it does not erase the limited professional final-user authorization or other statutory exceptions.

The live row's NpSG classification is materially corrected. Current German primary law expressly names 2-FDCK in BtMG Anlage II, which is the category of marketable but non-prescribable narcotics. BtMG § 3 makes the listed traffic routes authorization-based, and § 29 expressly criminalizes possession without a written acquisition permit as well as unauthorized handling, with a basic maximum of five years' imprisonment or a fine. NpSG § 1 Abs. 2 Nr. 1 excludes BtMG narcotics from the NpSG, so the legacy July 18, 2019 NpSG date and statement that possession is not subject to criminal penalty should not be retained. This conclusion addresses ordinary unlicensed handling and does not negate statutory authorization pathways.

The live production row was reopened from https://glad-minnow-656.convex.cloud for slug 2-fluorodeschloroketamine; its Japan value is status Illegal with notes that the substance is controlled as a designated substance. Stage A confirms the historical designated-drug context but the current MHLW notice says 2-FDCK was newly designated as a narcotic effective 2024-08-30 and that narcotic-designated substances cease to be designated drugs. Stage B confirms the current consolidated e-Gov schedule lists the exact chemical and salts at Article 1 item 109. The current Narcotics and Psychotropics Control Act supplies the applicable narcotic definition and possession/administration prohibitions, subject to its licensing and statutory medical exceptions. The legacy Illegal outcome is retained as a prohibition classification but corrected from designated drug to narcotic.

The legacy 'Illegal' row is substantively supported but materially under-specified. Current Singapore primary law expressly names 2-Fluorodeschloroketamine / 2-FDCK in the First Schedule's Class A controlled-drug list, and S 349/2020 records its 1 May 2020 commencement. The current consolidated schedule now presents it as paragraph 18 item (46), while the amendment inserted it as item (19ABF). Sections 5–8 establish that unauthorized trafficking, manufacture, import/export, possession and consumption of a controlled drug are offences. The canonical correction is prohibited, with the statutory authorization qualifier retained; the unsupported generic 'severe penalties' wording is not carried forward.

The legacy claim is materially supported as to Swiss control but corrected in category. The current official ordinance expressly names 2-Fluordeschlorketamin in Verzeichnis d, not Verzeichnis e. The ordinance defines e separately as raw materials and products with suspected narcotic-like effects. BAG guidance describes Verzeichnis d substances as prohibited narcotic drugs and explains the Article 8(5) exceptional-permit framework, so the canonical status is prohibited rather than an unscheduled or merely restricted category.

The legacy row is substantively supported: 2-Fluorodeschloroketamine fits the MDA Schedule 2 Part II paragraph 1(d) generic clause through the 2-amino-2-phenylcyclohexanone scaffold, N-alkyl substitution and phenyl-ring halide substitution. The clause was inserted by S.I. 2013/239, effective 26 February 2013. The canonical status is analog_covered rather than a named-substance status. The legacy notes should be qualified: sections 3, 4 and 5 state the prohibitions subject to regulations, licences and statutory exceptions, so possession, production, supply and import are not absolutely unlawful in every regulated or licensed circumstance.